Front Oncol:信迪利单抗(Sintilimab)二线或以上治疗晚期或转移性胃癌疗效的回顾性研究

2021-09-23 yd2015 MedSci原创

研究表明,信迪利单抗(Sintilimab)二线或以上治疗晚期或转移性胃癌是可行的治疗策略,而且在肠型患者中要优于非肠型患者。

胃癌是我国常见的恶性肿瘤之一,而且诊断时大部分处于局部晚期或转移性,导致治疗效果差,预后差。免疫治疗已经被用于多种肿瘤的治疗。基于ATTRACTION-02和KEYNOTE-059研究,nivolumab和pembrolizumab已分别在日本和美国被批准用于晚期胃癌的三线治疗。信迪利单抗(Sintilimab)是我国国产的PD-1抑制剂。在中国已经获批复发/难治性霍奇金淋巴瘤,而且在多种肿瘤中,包括胃癌,也正在进行研究。近期,来自我国河南省肿瘤医院的团队开展了回顾性研究,评估信迪利单抗(Sintilimab)二线或以上治疗晚期或转移性胃癌的疗效和安全性。相关结果发表在Frontiers in Oncology杂志上。

该研究回顾性分析了2019年3月至2020年7月在既往全身治疗后进展并接受sintilimab治疗的晚期或转移性胃癌患者。主要终点为无进展生存期(PFS)。次要终点包括客观缓解率(ORR)、疾病控制率(DCR)、总生存率(OS)和安全性。

研究纳入52例患者,中位年龄64岁(范围30 80岁),其中女性17例,男性35例。所有患者均诊断为晚期或复发;转移部位包括腹内淋巴结(65.4%)、肝脏(42.3%)、腹膜(28.8%)和肺(25%)。19例(36.5%)患者接受sintilimab作为二线治疗,33例患者(63.5%)为三线或以上治疗。8例患者接受sintilimab单药治疗,44例患者接受sintilimab联合治疗。44例患者接受联合治疗,24例患者接受sintilimab联合阿帕替尼治疗,20例患者接受sintilimab联合白蛋白-紫杉醇或伊立替康治疗。

                临床特征

总体人群中,未观察到CR, 8例患者达到PR, 26例患者达到SD, 18例患者出现PD。ORR和DCR分别为15.4%(8/52)和65.4%(34/52)。在肠型人群中, ORR和DCR分别为30.0%(6/20)和80.0%(16/20)。非肠型人群中, ORR和DCR分别为6.3%(2/32)和56.3%(18/32)。PD- L1阳性人群中,ORR和DCR分别为57.1%(4/7)和100%(7/7)。在PD- L1阴性人群中, ORR和DCR分别为7.1%(1/14)和64.3%(9/14)。在sintilimab单药治疗人群中,ORR和DCR分别为12.5%(1/8)和50.0%(4/8)。在联合治疗人群中,ORR和DCR分别为15.9%(7/44)和68.2% (30/44)。

           疗效评估

总体人群的中位PFS和OS分别为2.5个月(95% CI = 2.0 3.0)和5.8个月(95% CI = 4.9 6.7)。

              PFS和OS

sintilimab单药和联合组的中位PFS分别为1.5 个月(95% CI = 0.3–2.7) 和2.9个月 (95% CI =2.3–3.5) ,没有统计学差异(p = 0.088);而两组的OS分别为4.0个月 (95% CI = 0 8.7)和6.0 个月(95% CI = 5.0 7.0),也没有统计学差异(p = 0.133)。

          单药和联合治疗的PFS和OS

肠型和非肠型患者的中位PFS分别为4.0个月(95% CI = 3.1 4.8)和1.9个月(95% CI = 1.2 2.6) (p = 0.000);而中位OS分别为9.0个月(95% CI = 6.7 11.3)和4.1个月(95% CI = 2.7 5.4)(p = 0.000)。PD - L1阳性和阴性患者的中位PFS分别为5.0个月(95% CI = 4.0 6.0)和2.0个月(95% CI = 1.1 2.9)(p = 0.000)。PD-L1阳性和PD-L1阴性患者的中位OS分别为12.1个月(95% CI = 6.4 17.8)和4.1个月(95% CI = 2.0 6.2)(p = 0.027)。

               亚组分析PFS和OS

所有患者都发生不良反应。大多数不良反应(AEs)为1-2级。3-4级不良反应发生在23例(44.2%)患者中。

综上,研究表明,信迪利单抗(Sintilimab)二线或以上治疗晚期或转移性胃癌是可行的治疗策略,而且在肠型患者中要优于非肠型患者。

原始出处:

Nie C, Lv H, Liu Y, et al (2021) Clinical Study of Sintilimab as Second-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Retrospective Study. Front. Oncol. 11:741865. doi: 10.3389/fonc.2021.741865

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1241542, encodeId=1e3b124154291, content=<a href='/topic/show?id=329c2e376fa' target=_blank style='color:#2F92EE;'>#信迪利单抗#</a>与<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27376, encryptionId=329c2e376fa, topicName=信迪利单抗), TopicDto(id=83220, encryptionId=f9e2832202f, topicName=胃癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Aug 28 14:54:05 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735298, encodeId=87fb1e352982b, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Sat Feb 05 15:52:58 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912689, encodeId=982b1912689cc, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Sep 06 08:52:58 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866245, encodeId=374e186624569, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Sep 04 08:52:58 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386848, encodeId=0c0613868487d, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 25 12:52:58 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585717, encodeId=97221585e1708, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Sat Sep 25 12:52:58 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054298, encodeId=58ee1054298a1, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/798b9a11e1834c52b6667d71ec29a2fe/c4404e92055a461b85f5cf0c06bb8497.jpg, createdBy=06ab5182837, createdName=向阳花开, createdTime=Thu Sep 23 22:50:52 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054292, encodeId=f8d6105429201, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Sep 23 22:41:08 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054291, encodeId=8078105429133, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Thu Sep 23 22:39:14 CST 2021, time=2021-09-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1241542, encodeId=1e3b124154291, content=<a href='/topic/show?id=329c2e376fa' target=_blank style='color:#2F92EE;'>#信迪利单抗#</a>与<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27376, encryptionId=329c2e376fa, topicName=信迪利单抗), TopicDto(id=83220, encryptionId=f9e2832202f, topicName=胃癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Aug 28 14:54:05 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735298, encodeId=87fb1e352982b, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Sat Feb 05 15:52:58 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912689, encodeId=982b1912689cc, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Sep 06 08:52:58 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866245, encodeId=374e186624569, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Sep 04 08:52:58 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386848, encodeId=0c0613868487d, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 25 12:52:58 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585717, encodeId=97221585e1708, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Sat Sep 25 12:52:58 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054298, encodeId=58ee1054298a1, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/798b9a11e1834c52b6667d71ec29a2fe/c4404e92055a461b85f5cf0c06bb8497.jpg, createdBy=06ab5182837, createdName=向阳花开, createdTime=Thu Sep 23 22:50:52 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054292, encodeId=f8d6105429201, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Sep 23 22:41:08 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054291, encodeId=8078105429133, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Thu Sep 23 22:39:14 CST 2021, time=2021-09-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1241542, encodeId=1e3b124154291, content=<a href='/topic/show?id=329c2e376fa' target=_blank style='color:#2F92EE;'>#信迪利单抗#</a>与<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27376, encryptionId=329c2e376fa, topicName=信迪利单抗), TopicDto(id=83220, encryptionId=f9e2832202f, topicName=胃癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Aug 28 14:54:05 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735298, encodeId=87fb1e352982b, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Sat Feb 05 15:52:58 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912689, encodeId=982b1912689cc, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Sep 06 08:52:58 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866245, encodeId=374e186624569, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Sep 04 08:52:58 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386848, encodeId=0c0613868487d, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 25 12:52:58 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585717, encodeId=97221585e1708, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Sat Sep 25 12:52:58 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054298, encodeId=58ee1054298a1, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/798b9a11e1834c52b6667d71ec29a2fe/c4404e92055a461b85f5cf0c06bb8497.jpg, createdBy=06ab5182837, createdName=向阳花开, createdTime=Thu Sep 23 22:50:52 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054292, encodeId=f8d6105429201, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Sep 23 22:41:08 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054291, encodeId=8078105429133, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Thu Sep 23 22:39:14 CST 2021, time=2021-09-23, status=1, ipAttribution=)]
    2022-09-06 snf701207
  4. [GetPortalCommentsPageByObjectIdResponse(id=1241542, encodeId=1e3b124154291, content=<a href='/topic/show?id=329c2e376fa' target=_blank style='color:#2F92EE;'>#信迪利单抗#</a>与<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27376, encryptionId=329c2e376fa, topicName=信迪利单抗), TopicDto(id=83220, encryptionId=f9e2832202f, topicName=胃癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Aug 28 14:54:05 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735298, encodeId=87fb1e352982b, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Sat Feb 05 15:52:58 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912689, encodeId=982b1912689cc, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Sep 06 08:52:58 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866245, encodeId=374e186624569, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Sep 04 08:52:58 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386848, encodeId=0c0613868487d, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 25 12:52:58 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585717, encodeId=97221585e1708, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Sat Sep 25 12:52:58 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054298, encodeId=58ee1054298a1, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/798b9a11e1834c52b6667d71ec29a2fe/c4404e92055a461b85f5cf0c06bb8497.jpg, createdBy=06ab5182837, createdName=向阳花开, createdTime=Thu Sep 23 22:50:52 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054292, encodeId=f8d6105429201, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Sep 23 22:41:08 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054291, encodeId=8078105429133, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Thu Sep 23 22:39:14 CST 2021, time=2021-09-23, status=1, ipAttribution=)]
    2022-09-04 minlingfeng
  5. [GetPortalCommentsPageByObjectIdResponse(id=1241542, encodeId=1e3b124154291, content=<a href='/topic/show?id=329c2e376fa' target=_blank style='color:#2F92EE;'>#信迪利单抗#</a>与<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27376, encryptionId=329c2e376fa, topicName=信迪利单抗), TopicDto(id=83220, encryptionId=f9e2832202f, topicName=胃癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Aug 28 14:54:05 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735298, encodeId=87fb1e352982b, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Sat Feb 05 15:52:58 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912689, encodeId=982b1912689cc, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Sep 06 08:52:58 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866245, encodeId=374e186624569, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Sep 04 08:52:58 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386848, encodeId=0c0613868487d, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 25 12:52:58 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585717, encodeId=97221585e1708, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Sat Sep 25 12:52:58 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054298, encodeId=58ee1054298a1, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/798b9a11e1834c52b6667d71ec29a2fe/c4404e92055a461b85f5cf0c06bb8497.jpg, createdBy=06ab5182837, createdName=向阳花开, createdTime=Thu Sep 23 22:50:52 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054292, encodeId=f8d6105429201, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Sep 23 22:41:08 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054291, encodeId=8078105429133, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Thu Sep 23 22:39:14 CST 2021, time=2021-09-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1241542, encodeId=1e3b124154291, content=<a href='/topic/show?id=329c2e376fa' target=_blank style='color:#2F92EE;'>#信迪利单抗#</a>与<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27376, encryptionId=329c2e376fa, topicName=信迪利单抗), TopicDto(id=83220, encryptionId=f9e2832202f, topicName=胃癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Aug 28 14:54:05 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735298, encodeId=87fb1e352982b, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Sat Feb 05 15:52:58 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912689, encodeId=982b1912689cc, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Sep 06 08:52:58 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866245, encodeId=374e186624569, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Sep 04 08:52:58 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386848, encodeId=0c0613868487d, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 25 12:52:58 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585717, encodeId=97221585e1708, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Sat Sep 25 12:52:58 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054298, encodeId=58ee1054298a1, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/798b9a11e1834c52b6667d71ec29a2fe/c4404e92055a461b85f5cf0c06bb8497.jpg, createdBy=06ab5182837, createdName=向阳花开, createdTime=Thu Sep 23 22:50:52 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054292, encodeId=f8d6105429201, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Sep 23 22:41:08 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054291, encodeId=8078105429133, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Thu Sep 23 22:39:14 CST 2021, time=2021-09-23, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1241542, encodeId=1e3b124154291, content=<a href='/topic/show?id=329c2e376fa' target=_blank style='color:#2F92EE;'>#信迪利单抗#</a>与<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27376, encryptionId=329c2e376fa, topicName=信迪利单抗), TopicDto(id=83220, encryptionId=f9e2832202f, topicName=胃癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Aug 28 14:54:05 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735298, encodeId=87fb1e352982b, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Sat Feb 05 15:52:58 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912689, encodeId=982b1912689cc, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Sep 06 08:52:58 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866245, encodeId=374e186624569, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Sep 04 08:52:58 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386848, encodeId=0c0613868487d, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 25 12:52:58 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585717, encodeId=97221585e1708, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Sat Sep 25 12:52:58 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054298, encodeId=58ee1054298a1, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/798b9a11e1834c52b6667d71ec29a2fe/c4404e92055a461b85f5cf0c06bb8497.jpg, createdBy=06ab5182837, createdName=向阳花开, createdTime=Thu Sep 23 22:50:52 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054292, encodeId=f8d6105429201, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Sep 23 22:41:08 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054291, encodeId=8078105429133, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Thu Sep 23 22:39:14 CST 2021, time=2021-09-23, status=1, ipAttribution=)]
    2021-09-23 向阳花开

    👍

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1241542, encodeId=1e3b124154291, content=<a href='/topic/show?id=329c2e376fa' target=_blank style='color:#2F92EE;'>#信迪利单抗#</a>与<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27376, encryptionId=329c2e376fa, topicName=信迪利单抗), TopicDto(id=83220, encryptionId=f9e2832202f, topicName=胃癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Aug 28 14:54:05 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735298, encodeId=87fb1e352982b, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Sat Feb 05 15:52:58 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912689, encodeId=982b1912689cc, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Sep 06 08:52:58 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866245, encodeId=374e186624569, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Sep 04 08:52:58 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386848, encodeId=0c0613868487d, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 25 12:52:58 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585717, encodeId=97221585e1708, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Sat Sep 25 12:52:58 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054298, encodeId=58ee1054298a1, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/798b9a11e1834c52b6667d71ec29a2fe/c4404e92055a461b85f5cf0c06bb8497.jpg, createdBy=06ab5182837, createdName=向阳花开, createdTime=Thu Sep 23 22:50:52 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054292, encodeId=f8d6105429201, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Sep 23 22:41:08 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054291, encodeId=8078105429133, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Thu Sep 23 22:39:14 CST 2021, time=2021-09-23, status=1, ipAttribution=)]
    2021-09-23 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1241542, encodeId=1e3b124154291, content=<a href='/topic/show?id=329c2e376fa' target=_blank style='color:#2F92EE;'>#信迪利单抗#</a>与<a href='/topic/show?id=f9e2832202f' target=_blank style='color:#2F92EE;'>#胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27376, encryptionId=329c2e376fa, topicName=信迪利单抗), TopicDto(id=83220, encryptionId=f9e2832202f, topicName=胃癌)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Sun Aug 28 14:54:05 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735298, encodeId=87fb1e352982b, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Sat Feb 05 15:52:58 CST 2022, time=2022-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912689, encodeId=982b1912689cc, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Tue Sep 06 08:52:58 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1866245, encodeId=374e186624569, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sun Sep 04 08:52:58 CST 2022, time=2022-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386848, encodeId=0c0613868487d, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Sep 25 12:52:58 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585717, encodeId=97221585e1708, content=<a href='/topic/show?id=e76840556f9' target=_blank style='color:#2F92EE;'>#回顾性研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40556, encryptionId=e76840556f9, topicName=回顾性研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=037917278808, createdName=jiyangfei, createdTime=Sat Sep 25 12:52:58 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054298, encodeId=58ee1054298a1, content=👍, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210923/798b9a11e1834c52b6667d71ec29a2fe/c4404e92055a461b85f5cf0c06bb8497.jpg, createdBy=06ab5182837, createdName=向阳花开, createdTime=Thu Sep 23 22:50:52 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054292, encodeId=f8d6105429201, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Sep 23 22:41:08 CST 2021, time=2021-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1054291, encodeId=8078105429133, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Thu Sep 23 22:39:14 CST 2021, time=2021-09-23, status=1, ipAttribution=)]
    2021-09-23 医鸣惊人

    认真学习了

    0

相关资讯

J Thorac Oncol:Sintilimab联合化疗可显著延长非鳞状NSCLC患者的总生存期!

在化疗方案中加入Sintilimab可明显延长非鳞状NSCLC患者的总生存期

JTO:信迪利单抗(Sintilimab)联合培美曲塞+铂类一线治疗局部进展或转移性非鳞状非小细胞肺癌的OS结果更新: 3期临床研究(ORIENT-11)。

ORIENT-11研究表明,信迪利单抗联合培美曲塞+铂类化疗一线治疗明显改善晚期非鳞状NSCLC患者的OS。